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Abstract 
Background: Artemisinin resistant Plasmodium falciparum has emerged in the countries of the Greater Mekong 
sub‑region posing a serious threat to global malaria elimination efforts. The relationship of artemisinin resistance to 
treatment failure has been unclear.
Methods: In annual studies conducted in three malaria endemic provinces in the south of Vietnam (Binh Phuoc, 
Ninh Thuan and Gia Lai) between 2011 and 2015, 489 patients with uncomplicated P. falciparum malaria were enrolled 
in detailed clinical, parasitological and molecular therapeutic response assessments with 42 days follow up. Patients 
received the national recommended first‑line treatment dihydroartemisinin‑piperaquine for three days.
Results: Over the 5 years the proportion of patients with detectable parasitaemia on day 3 rose steadily from 38 
to 57% (P < 0.001). In Binh Phuoc province, the parasite clearance half‑life increased from 3.75 h in 2011 to 6.60 h in 
2015 (P < 0.001), while treatment failures rose from 0% in 2012 and 2013, to 7% in 2014 and 26% in 2015 (P < 0.001). 
Recrudescence was associated with in vitro evidence of artemisinin and piperaquine resistance. In the treatment fail‑
ures cases of 2015, all 14 parasite isolates carried the C580Y Pfkelch 13 gene, marker of artemisinin resistance and 93% 
(13/14) of them carried exoE415G mutations, markers of piperaquine resistance.
Conclusions: In the south of Vietnam recent emergence of piperaquine resistant P. falciparum strains has accelerated 
the reduced response to artemisinin and has led to treatment failure rates of up to 26% to dihydroartemisinin‑pipe‑
raquine, Vietnam’s current first‑line ACT. Alternative treatments are urgently needed.
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Background
Over the past 30  years there have been substantial 
reductions in malaria mortality and morbidity across 
the Greater Mekong sub-region. This has been driven 
largely by increased deployment of artemisinin-based 
combination therapy (ACT) for falciparum malaria 
which have replaced the monotherapies which suc-
cessively fell to resistance. In Vietnam, the number of 
clinical cases of malaria decreased from 1,672,000 with 
4650 deaths in 1991 to 19,252 with 3 deaths in 2015 [1]. 
Dihydroartemisinin-piperaquine (DP) was adopted in 
2005 as first-line treatment and is the most extensively 
used anti-malarial drug in Vietnam. The success of the 
National Malaria Control Programme (NMCP) led to the 
initiation of “Malaria Elimination by the year of 2025,” 
a project endorsed with strong political commitment. 
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Neighbouring countries have also set malaria elimina-
tion targets for the near future. These laudable objec-
tives are now threatened by the emergence and spread of 
artemisinin resistant Plasmodium falciparum. First rec-
ognized in Western Cambodia 10 years ago, artemisinin 
resistant malaria parasites are now prevalent across the 
Greater Mekong subregion from the Myanmar-India 
border in the west to the coast of Vietnam in the East 
[2, 3]. To characterize the extent of artemisinin resist-
ance and its effects on therapeutic responses to ACT, the 
Global Plan for Artemisinin Resistance Containment [4] 
recommended regular in  vivo and in  vitro assessments. 
This study reports on the results of sequential studies 
conducted in the southern provinces Binh Phuoc, Ninh 
Thuan, and Gia Lai of Vietnam.
Methods
Study sites
The study was conducted from August 2011 to Decem-
ber 2015 in (i) the Bu Gia Map and Dak O communes 
located in the Bu Gia Map district, Binh Phuoc province, 
130 km northeast of Ho Chi Minh City and 100 km west 
of the Cambodian border (In 1989, Binh Phuoc was the 
first province in Vietnam to use artemisinin monother-
apy); (ii) the IaTo commune, Ia Grai district, and then 
the Krong Pa Medical Center (this study site replaced 
the laTo site in 2012 because of slow recruitment), both 
are in Gia Lai province in the southern highlands; (iii) 
the Phuoc Thang commune, Bac Ai district, Ninh Thuan 
province in central Vietnam (2013–present) (Fig. 1).
Recruitment of study participants
Inclusion and exclusion criteria followed the World 
Health Organization’s protocol for surveillance of the 
therapeutic efficacy of anti-malarial medicines [5]. 
Patients presenting with uncomplicated P. falciparum 
malaria detected using microscopy, aged three years and 
above with an asexual parasitaemia between 10,000- and 
200,000 parasites/µL were invited to participate in the 
surveillance program. Participants aged 15  years and 
above provided written informed consent. Parents or 
guardians granted informed consent on behalf of their 
children. A minimum sample of 50 patients was required 
for the study to be representative (n ≥ 50) [5]. We there-
fore planned to enroll 50–75 subjects per site per year.
Treatment of malaria and follow‑up
Patients with uncomplicated malaria who met the study 
inclusion criteria were enrolled, screened, and treated 
on-site daily with dihydroartemisinin-piperaquine 
(DP) (Arterakin, CV Artecan) for 3  days, following the 
National Malaria Treatment Guidelines [6]. DP tablets 
containing 40  mg of dihydroartemisinin and 320  mg of 
piperaquine phosphate were obtained from OPC Phar-
marceutical Joint-Stock Company (Ho Chi Minh, Viet-
nam) and distributed by the NMCP. The number of DP 
tablets administered at 0, 8, 24, and 48  h was adminis-
tered according to body weight (Additional file  1). All 
doses were administered and recorded under the super-
vision of a qualified member of the staff designated by 
the principal investigator. The subjects were observed for 
30  min for adverse reactions or for vomiting after tak-
ing the medication. Any patient who vomited during this 
period was re-treated with the same dose and observed 
for a further 30 min. If vomiting occurred between 30 and 
60 min after administration, half the dose was repeated. 
If the patient vomited again, he or she was withdrawn 
and offered rescue therapy. Patients were monitored for 
42  days. The follow-up comprised a fixed schedule of 
examinations on days 3, 7, 14, 21, 28, 35, 42 and included 
clinical and laboratory testing. PCR genotyping was used 
to distinguish between recrudescence and reinfection [7].
Clinical and laboratory procedures
Microscopy examination of blood
Thick and thin blood films were examined at screening 
(day 0) then every 6 h until two consecutive slides were 
negative as well as on each day of scheduled follow up 
or on any other day if the patient returned and parasito-
logical reassessment required. Specimens were labeled 
to maintain anonymity (screening or study number, day 
of follow-up, and date). Thick and thin blood smears 
were examined were stained with 10% Giemsa in pH 7.2 
buffer solution for 15 min. Parasitaemia was estimated by 
counting the number of asexual parasites per 500 leuco-
cytes in the thick blood film or per 1000 red blood cells 
on a thin film then calculated followed WHO guideline. 
All slides were read by two qualified microscopists inde-
pendently, and the average of the two counts was taken as 
the parasite density. Blood smears with discordant results 
(differences in assessments of species, parasite den-
sity >50%, or the presence of parasites) were re-examined 
by a third independent microscopist, and parasite densi-
ties were calculated by averaging the two closest counts 
[5].
Genotyping of malaria parasites
To minimize discomfort from repeated finger pricks, four 
drops of blood were collected on Whatman 3MM filter 
paper (Whatman, UK) during screening or enrolment, 
and each time a blood smear or blood draw sample was 
required according to the protocol on day 7 and after. 
Specimens were anonymized and stored in individual 
plastic bags containing desiccant pouches that were pro-
tected from light, humidity, and extreme temperatures. 
If treatment failed, paired filter paper samples were used 
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for parasite DNA extraction and genotyping based on 
polymorphisms in the genes encoding the merozoite sur-
face proteins MSP-2 and MSP-1 as well as GLURP follow 
standard procedures [7].
K13 single‑nucleotide polymorphism (SNPs) genotyping
Taqman SNP genotyping was used to detect mutations 
in the K13-propeller gene at the field sites within 1 or 
2 days after collection. The total genomic DNA from the 
dried blood spot samples were extracted by a MagNa 
Pure 96 Instrument automated extraction system using 
MagNa Pure 96 DNA and Viral NA Small Volume Kit 
(Roche, Switzerland). Seven positions on K13-propeller 
gene (Y493H, R539T, I543T, P553L, C580Y, V568G and 
P574L) were chosen to genotyping based on result of pre-
vious reports on K13 in Vietnam parasite population [8, 
9]. Ten ng of DNA template was genotyped at 7 positions 
described above separately in 10  μL volume reactions 
including 0.5 μL Taqman primer probe mix (Applied Bio-
systems), 5  μL Light Cycler Probe master mix (Roche, 
Switzerland). The cycling conditions were 10 min at 95 °C 
followed by 50 cycles of 15 s at 95 °C, 1 min at 60 °C and 
hold at 37  °C for 15 min. Allelic discrimination analysis 
was performed to determine the genotype of the sam-
ples. All samples with mutations and 30 samples with 
no mutations at 7 SNPs described above (randomly cho-
sen) were retested by capillary sequencing to confirm the 
results of SNP genotyping.
In‑vitro susceptibility assays
Ex vivo responses to dihydroartemisinin (DHA) and 
in  vitro reponses to piperaquine were assessed in 9/14 
P. falciparum samples of recrudescence cases (collected 
from patients involved in the DP efficacy monitoring 
study in 2015–2016 in Binh Phuoc Province) by the ring 
stage survival assay (RSA) [10] and piperaquine survival 
assay (PSA) [11], respectively. The results were expressed 
as the survival rate of parasites after 6  h drug exposure 
for RSA and 48  h for PSA. The DHA and piperaquine 
sensitive 3D7 and K1 P. falciparum lines were used as 
controls in the RSA and PSA.
Piperaquine resistant marker testing
DNA samples from recrudescence cases and ACPR 
cases were sent to Welcome Trust Sanger Institute 
for genotyping to detect mutation at position 415 in 
Fig. 1 The study sites in Vietnam
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putative exonuclease gene (exoE415G) followed a proto-
col described recently [12]. Copy number of plasmepsin 2 
encoding gene were detected by real time qPCR followed 
a procedure shared by the same group [12].
Outcome measures
The primary objective of this study was to monitor for 
artemisinin resistance by assessing parasite clearance 
times (PCT100), specifically, the proportion of patients 
with clearance times >72 h after starting DP treatment 
[13]. The PCT100 was defined as number of hours from 
the first treatment dose to the first of two consecutive 
negative thick blood films for asexual P. falciparum 
parasites in 500 fields. Secondary outcomes were as 
follows: (i) The parasite clearance half-life (PC1/2) was 
defined as the time for parasitaemia to decrease by 
50% during the log-linear phase of parasite clearance 
as calculated by the WorldWide Antimalarial Resist-
ance Network parasite clearance estimator [13]. (ii) The 
fever clearance time (FCT) was defined as the number 
of hours from the first treatment dose to the start of 
the first sustained 24 h period without fever (<37.5 °C). 
(iii) Treatment failure was defined according to WHO 
guidelines [5] [proportion of early treatment failures 
(ETFs), late clinical failures (LCFs), late parasitologi-
cal failures (LPFs), and adequate clinical and parasito-
logical responses (ACPRs) by day 42]. PCR-uncorrected 
and PCR-corrected failure rates were reported. Recru-
descence was defined as detection of identical alleles 
for each of the three polymorphic markers in the pre-
treatment and post-treatment samples. Infections in 
which one or more alleles differed were classified as 
new infections [7]. (iv) The relationship between treat-
ment outcomes and the prevalence of the K13-propeller 
mutations was characterized.
Statistical analysis
The proportion of subjects with a PCT >72 h was calcu-
lated using the Kaplan–Meier method. The risk of treat-
ment failure was estimated using the Kaplan–Meier 
estimator (intention-to-treat analysis) and as a propor-
tion of evaluable patients only (per protocol analysis). At 
each site, changes in outcomes were assessed using lin-
ear trend tests. Specifically, the outcome was regressed 
according to calendar time using the Cox proportional 
hazards model (parasite clearance time, fever clear-
ance time, and intention-to-treat analysis of the time to 
treatment failure), linear regression (parasite clearance 
half-life), or logistic regression (per protocol analysis of 
treatment failures and prevalence of the K13-propeller 
mutation). All analyses were performed using R v.3.3.1 
software (R Foundation for Statistical Computing, 
Vienna, Austria).
Ethics
The protocol, informed consent documents, relevant sup-
porting information, and all patient recruitment informa-
tion were approved by the Ethics Committees of the Ho 
Chi Minh and Qui Nhon Institutes of Malaria, Parasitol-
ogy and Entomology and the Oxford University Tropical 
Research Ethics Committee. Any person who decided 
not to participate in the study was examined, treated, and 
followed by health facility staff according to the standard 
of care recommended by the Ministry of Health [6].
Results
Between August 2011 and December 2015, 489 patients 
with uncomplicated P. falciparum malaria were recruited: 
253 in Binh Phuoc; 188 in Ninh Thuan; and 48 in Gia Lai. 
The 42-day follow-up schedule was completed by 423 
(87%) subjects (Fig.  2). Adults (>15  years of age) repre-
sented 77% (375/489) of the patients, and 95% (471/489) 
were febrile upon admission (Table 1). The proportion of 
patients with a microscopy detected parasitaemia on day 
3 (D3) post-DP treatment was highest in the Binh Phuoc 
site and increased progressively with time: 38, 41, 54, and 
57% in 2012, 2013, 2014, and 2015, respectively (P < 0.001) 
(Fig.  3). In Ninh Thuan, the percentage remained 
low (<10%), and the differences were not significant 
(P =  0.29). In Gia Lai, patients were only recruited dur-
ing 2011 and 2015 The D3 positivity rates were 0% in Iato 
versus 55% in Krong Pa (P < 0.001). The parasite clearance 
half-life in Binh Phuoc increased from 3.75 h in 2011 to 
6.60 h in 2015 (P < 0.001) (Tables 2, 3, 4; Fig. 3). One early 
treatment failure occurred at Binh Phuoc (Table 2). This 
patient was febrile with a positive blood smear on day 3, 
but recovered fully by the end of treatment. Treatment 
failure rates were highest in Binh Phuoc, and increased 
significantly over time (P < 0.001) as follows: 0% in 2012 
and 2013 and 7 and 26% in 2014 and 2015, respectively 
(Table 2). There were only two late treatment failures in 
Ninh Thuan (Table 3) and none in Gia Lai (Table 4).
Samples for evaluation of mutations were available for 
481 subjects. K13-propeller mutations (n  =  151, 31%) 
were as follows: 109, C580Y; 24, Y493H; 10, P553L; 7, 
I543T and 1 V568G (Additional File 2). Baseline parasi-
taemia was associated with the K13-propeller mutation 
(P value = 0.37 [linear regression, adjusted for site]). The 
median (IQR) parasite clearance half-life in patients with 
a K13-propeller mutation was 6.59 h (5.14–7.42 h) com-
pared with 2.05  h (1.66–2.90  h) in subjects without the 
mutation [P < 0.001 (linear regression, adjusted for site)]. 
Half-lives were longer in subjects with a C580Y mutation 
compared with those with Y493H mutations, although 
the difference was not statistically significant (median 
6.70 and 5.42 h, P = 0.07). Among the 17 subjects with 
PCR-corrected treatment failure in Binh Phuoc, 15 had a 
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K13-propeller mutation (all C580Y), one did not have the 
mutation, and one did not provide a sample.
Ex vivo responses to DHA were measured in 64% 
(9/14) of P. falciparum isolates collected from recru-
descent patients in 2015 by RSA and all were resistant 
to DHA (survival rate  >1), with a median survival rate 
of 14.29% (IQR 4.76%, 23.51%). The 9 isolates were also 
tested in the PSA and all were resistant to piperaquine, 
with survival rate  ≥10% (Fig.  4). The median survival 
rate after exposure to 200 nM of piperaquine was 20.72% 
(IQR 8.28%, 30.07%). The RSA and PSA were also carried 
out on isolates from two patients who experienced an 
ACPR response to DP.
The exoE415G mutation, which has been reported 
associated with increased tolerance to piperaquine [12] 
were found in 93% (13/14) isolates collected from recru-
descent patients in 2015. Due to limited DNA amount 
of the recrudescent samples, plasmepsin 2 amplification 
was measured in 71% (10/14) of the samples. Eight of 
them (80%) had multi-copies of this gene (Fig. 5).
Discussion
The widespread use of artemisinin and its derivatives in 
Vietnam has been a major factor underlying the marked 
reduction in malaria mortality and morbidity in the 
country. Until recently the nationally recommended 
Total of patient was screened in the study: 20,483
Number of P.falciparum: 1,177




P.falciparum:        124
P.vivax:                203
Mixed infection:     7
Recruited: 48
LFU and WTH: 5





P.falciparum:         299
P.vivax:                 71
Mixed infection:      6
Recruited: 188
LFU and WTH: 25





P.falciparum:        754
P.vivax:             878
Mixed infection:   100
Recruited: 253
LFU and WTH: 36
Completed 42 day FU
217
Fig. 2 Study flow diagram
Table 1 Patient characteristics at enrolment sites in Vietnam
Characteristic Binh Phuoc
(N = 253)
NinhThuan (N = 188) Gia Lai
(N = 48)
Age [years]–median (IQR) 24 (18.33) 16 (10.26) 27 (22.29)
Children 3–14 years old‑n (%) 23/253 (9.1%) 89/188 (47.3%) 1/48 (2.1%)
Female gender–n (%) 39/253 (15%) 70/188 (37%) 3/48 (6%)
Temperature [°C]–median [IQR] 39.0 (38.3–39.5) 38.8 (38.0–39.5) 39.5 (39.0–40.0)
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ACT, dihydroartemisinin-piperaquine, retained excellent 
efficacy throughout the country.
Since the first recognition of artemisinin resistance 
in Cambodia, studies have been conducted to assess 
whether resistance had emerged in or spread to Vietnam, 
and what impact that would have on treatment efficacy. 
In 2010–2011, a randomized controlled clinical trial of 
166 patients with uncomplicated P. falciparum malaria 
in the Binh Phuoc area showed that the proportion of 
patients with parasite clearance times >72 h ranged from 
22 to 25%, depending on the dose of artesunate given 
(2 or 4  mg/kg/day). The corresponding median parasite 
clearance half-lives (PC1/2) for were <5 h. Both indicated 
a high prevalence of slow parasite clearance. Although 
there were two ETFs (4%) and one late clinical failure 
(2%) in the lower dose artesunate (2  mg/kg/day) group, 
the PCR-corrected ACPR rates in the three groups were 
94, 100, and 100% [14, 15]. This showed that artemisinin 
Fig. 3 Proportion of patients with positive smear on day 3, parasite 
clearance half‑life (PC1/2) and the treatment failure rate follow‑
ing dihydroartemisin–piperaquine treatment in Binh Phuoc from 
2012–2015 in Vietnam
Table 2 Annual clinical and parasite responses to dihydroartemisinin-piperaquine treatment of uncomplicated Plasmo-
dium falciparum malaria in Binh Phuoc province, Vietnam
* P values are based on linear trend tests
APCR adequate clinical and parasitological responses
Characteristic 2012 (n = 50) 2013 (n = 66) 2014 (n = 65) 2015 (n = 72) P value*
Fever clearance time [hours]
 Median (IQR) [hours] 24 (18.30) 18 (12.24) 24 (18.36) 24 (18.36) <0.001
Parasite clearance time (PCT100)
 Median (IQR) [hours] 63 (48.84) 60 (36.90) 78 (36.168) 78 (60.96) 0.002
 Proportion with PCT > 72 h 38% (19/50) 41% (29/66) 54% (35/65) 57% (41/72)
Parasite clearance half‑ life PC1/2 [hours]
 Median (IQR) 3.75 (2.45;6.56) 4.11 (2.10;6.27) 5.80 (2.45;7.14) 6.60 (4.65;8.03) <0.001
 Geometric mean (95% CI) 3.94 (3.38;4.60) 3.67 (3.16;4.26) 4.29 (3.66;5.03) 5.52 (4.84;6.29)
 T1/2 > 5 h 20/50 (40%) 27/64 (42%) 36/64 (56%) 51/69 (74%)
Treatment outcome (WHO)
 APCR# 47/50 (94%) 55/66 (83%) 43/65 (66%) 40/72 (56%)
 Early treatment failure 0/50 (0%) 0/66 (0%) 1/65 (2%) 0/72 (0%)
 Clinical treatment failure 0/50 (0%) 0/66 (0%) 1/65 (2%) 8/72 (11%)
 Parasitological treatment failure 2/50 (4%) 1/66 (2%) 5/65 (8%) 12/72 (17%) –
 Withdrawal 1/50 (2%) 4/66 (6%) 2/65 (3%) 3/72 (4%)
 Loss to follow‑up 0/50 (0%) 6/66 (9%) 13/65 (20%) 9/72 (13%)
Risk of failure [PCR—uncorrected]
 Uncorrected Kaplan–Meier estimate (ITT) 4% 2% 12% 30% <0.001
 Uncorrected proportion (per protocol) 2/49 (4%) 1/56 (2%) 7/50 (14%) 20/60 (33%) <0.001
Risk of failure [PCR—corrected]
 Corrected Kaplan–Meier estimate (‘ITT’) 0% 0% 5% 22% <0.001
 Corrected Proportion (‘per protocol’) 0/47 (0%) 0/55 (0%) 3/46 (7%) 14/54 (26%) <0.001
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resistance was present in Vietnam but had not yet 
affected the efficacy of the first-line treatment.
This study reports longitudinal clinical, parasitological 
and molecular surveillance over a five year period from 
malaria endemic areas in the south of the country close 
to Eastern Cambodia. In Binh Phuoc province between 
2012 and 2015 the proportion of patients with parasites 
still present on day 3 after starting DP treatment has pro-
gressively increased from 38 to 57%, with a correspond-
ing reduction in cure rates from 0 to 26% (PCR corrected 
as per protocol). It provides unequivocal evidence of 
worsening artemisinin resistance and it shows that this 
has recently been associated with a rapid deterioration in 
the efficacy of DP. This strongly suggests that piperaquine 
resistance has arisen upon a background of artemisinin 
resistance reported recently from Cambodia [16]. The 
in vitro and molecular studies provided support for this; 
all patients who failed treatment were infected with K13 
mutated parasites, and the parasites from recrudescent 
infections had median in vitro PSA survival rate of 39.2% 
compared with 0.17% in the patients who were cured 
with DP. Artemisinin-resistant K13 mutants with ex vivo 
PSA survival rates ≥10% were associated with a 32-fold 
higher risk of recrudescence [11]. It is notable that all 14 
recrudescent patients in 2015–2016 were infected with 
the C580Y PfK13 genotype, which may indicate a recent 
hard selective sweep by a successful multi-drug resistant 
lineage.
While piperaquine was effective the DP combination 
provided high cure rates, but the reduced anti-malar-
ial effect associated with artemisinin resistance places 
greater selection pressure on the partner drug, and when 
resistance to that occurs, the combination predictably 
fails. The detection of markers for piperaquine and DP 
treatment failure in the recrudescent patients also sup-
ported this. Among all the tested recrudescent para-
sites collected in 2015–2016, 93% (13/14) of them have 
exoE415G mutations and 80% (8/10) have multi copies 
of the plasmepsin 2 gene. It may indicate that resistance 
to piperaquine occurred. There has been insufficient 
attention to the protection of new anti-malarial medi-
cines. Strategies such as deployment of multiple first line 
Table 3 Annual clinical and parasite responses to dihydroartemisinin-piperaquine treatment of uncomplicated Plasmo-
dium falciparum malaria in Ninh Thuan province, Vietnam
* P values are based on linear trend tests
APCR adequate clinical and parasitological responses
Characteristic 2013 (n = 77) 2014 (n = 56) 2015 (n = 55) P value*
Parasite clearance time (PCT100)
 Median (IQR) [hours] 36 (24.42) 30 (24.36) 30 (24.36) 0.29
 Proportion with PCT > 72 h 5% (4/77) 7% (4/56) 2% (1/55)
Parasite clearance half‑ life T1/2 [hours]
 Median (IQR) 1.73 (1.38; 2.05) 1.78 (1.44; 2.36) 2.16 (1.75; 2.73) 0.29
 Geometric mean (95% CI) 1.84 (1.66; 2.03) 1.98 (1.73; 2.27) 2.19 (2.01; 2.39)
 T1/2 > 5 h 5/76 (7%) 5/56 (9%) 1/54 (2%)
Fever clearance time [hours]
 Median (IQR) [hours] 30 (24.54) 18 (12.30) 18 (12.24) <0.001
Treatment outcome (WHO)
 APCR# 62/77 (81%) 45/56 (80%) 43/55 (78%) –
 Early treatment failure 0/77 (0%) 0/56 (0%) 0/55 (0%)
 Clinical treatment failure 3/77 (4%) 1/56 (2%) 0/55 (0%)
 Parasite treatment failure 5/77 (6%) 1/56 (2%) 2/55 (4%)
 Withdrawal 2/77 (3%) 0/56 (0%) 0/55 (0%)
 Loss to follow‑up 5/77 (6%) 9/56 (16%) 10/55 (18%)
Risk of failure [PCR‑uncorrected]
 Uncorrected Kaplan–Meier estimate (ITT) 11% 4% 4% 0.046
 Uncorrected proportion (per protocol) 8/70 (11%) 2/47 (4%) 2/45 (4%) 0.05
Risk of failure [PCR‑corrected]
 Corrected Kaplan–Meier estimate (ITT) 0% 4% 0% 0.81
 Corrected proportion (per protocol) 0/62 (0%) 2/47 (4%) 0/43 (0%) 0.80






C580Y: 2/55 (4%) 0.53
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Table 4 Annual clinical and parasite responses to dihydroartemisinin-piperaquine treatment of uncomplicated Plasmo-
dium falciparum malaria in Gia Lai province, Vietnam
* P values are based on linear trend tests
APCR adequate clinical and parasitological responses
Characteristic 2011 (n = 21) 2015 (n = 27) P value*
Parasite clearance time (PCT100)
 Median (IQR) [hours] 36 (30,42) 96 (54, NA) <0.001
 Proportion with PCT > 72 h 0% (0/21) 55% (15/55)
Parasite clearance half‑ life T1/2 [hours]
 Median (IQR) 1.97 (1.66, 2.59) 6.88 (2.84, 7.74) <0.001
 Geometric mean (95% CI) 2.19 (1.86, 2.59) 5.19 (4.07, 6.62)
 T1/2 > 5 h 0/21 (0%) 18/26 (69%)
Fever clearance time [hours]
Median (IQR) [hours] 30 (18.30) 36 (24.54) 0.001
Treatment outcome (WHO)
 APCR# 17/21 (81%) 24/27 (89%) –
 Early treatment failure 0/21 (0%) 0/27 (0%)
 Clinical treatment failure 0/21 (0%) 0/27 (0%)
 Parasitological treatment failure 0/21 (0%) 2/27 (7%)
 Withdrawal 2/21 (10%) 0/27 (0%)
 Loss to follow‑up 2/21 (10%) 1/27 (4%)
Risk of failure [PCR‑uncorrected]
 Uncorrected Kaplan–Meier estimate (ITT) 0% 8% 0.22
 Uncorrected proportion (per protocol) 0/17 (0%) 2/26 (8%) 0.22
Risk of failure [PCR‑corrected]
 Corrected Kaplan–Meier estimate (ITT) 0% 0% –
 Corrected proportion (per protocol) 0/17 (0%) 0/24 (0%) –




Fig. 4 Ex vivo response to DHA and in vitro response to piperaquine of parasites collected from patients following dihydroartemisin–piperaquine 
treatment using ring stage assay (RSA) and piperaquine survival assay (PSA), respectively. Black dots represented for parasites from recrudescent 
cases, white dots represented for parasite from ACPR cases. The Plasmodium falciparum lines of 3D7 and K1 are controls
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therapies are needed when effective alternatives are avail-
able [17]. In Vietnam, alternatives to DP are limited.
These findings present policymakers in Vietnam with a 
dilemma. The currently recommended second-line regi-
men combines quinine with doxycycline. But this regi-
men is not well tolerated and adherence to the required 
7-day regimen is likely to be poor. The combination of 
artesunate with mefloquine may serve as an alternative. 
Vietnam used mefloquine both as a monotherapy and 
in an ACT (artesunate-mefloquine) since the 1990s. In 
2005, foreign financial support ceased, and the NMCP of 
Vietnam, therefore, switched to locally produced DP as 
first-line treatment for falciparum malaria. In 2002–2003, 
a 2-day regimen of DHA-mefloquine (300  mg DHA at 
0 h, then 300 mg DHA plus 750 mg mefloquine at 24 h) 
was evaluated at Binh Thuan and Binh Phuoc provinces 
and found to be 88.6% efficacious with a 42-day follow-up 
period. However, the limitation of the study was that it 
was not PCR corrected for differentiating rescrudescence 
from reinfection, and it is quite likely that a total dose of 
artesunate (12 mg/kg) plus mefloquine (25 mg/kg) given 
over 3  days would have been more effective. A 3-day 
artesunate-mefloquine regimen is presently being used 
in Cambodia in areas of DP treatment failure with cure 
rates of >99% (Chanaki et al. pers. comm.). A disadvan-
tage of the mefloquine containing regimens is that they 
are not as well tolerated as DP [18–20]. Atovaquone–
proguanil (ATQ–PG) was suggested as a non-artemisinin 
containing anti-malarial treatment option. ATQ–PG was 
assessed in a small trial conducted in 2003 by the NMCP 
of Vietnam (unpublished data) and the overall cure rate 
(CI) was 86% (76–98%) [21]. This is still lower than the 
95% benchmark recommended by WHO. Recently, an 
in  vitro study provided evidence that ATQ–PG may be 
a useful stopgap for DP failed cases [22], but a previ-
ous study has also shown that this combination remains 
susceptible to developing resistance [23]. Furthermore, 
because of the high costs of this drug ATQ–PG has not 
also been considered as an alternative treatment by the 
Vietnam NMCP.
Artemether-lumefantrine (AL, Coartem®) may be 
another treatment option, but no clinical trial to assess 
AL has been conducted in Vietnam over the last 20 years. 
A pilot trial was conducted in 2003 that resulted in 100% 
(45/45) APCR rate with 28 day follow-up (personal com-
munication). However, Vietnam’s NMCP has not con-
sidered AL as viable treatment alternative to DP due to 
financial constraints. The future may belong to newer 
anti-malarials, such as cipargamin (KAE 609), KAF 156, 
and artefenomel (OZ 439), but these are in phase II of 
development [24] and will likely not reach the market 
until 2020.
Conclusion
The authors conclude that there is no current medicine 
available to Vietnam’s national treatment guideline com-
mittee that meets the WHO criteria of being, “based on 
an average cure rate of >95%, as assessed in clinical tri-
als.” There is an urgent requirement to evaluate alterna-
tive treatments with other available forms of ACT and to 
develop new anti-malarial drugs given standard courses 
of ACT are failing.
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